Comparative Pharmacology
Head-to-head clinical analysis: APIDRA SOLOSTAR versus INSULIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA SOLOSTAR versus INSULIN.
APIDRA SOLOSTAR vs Insulin
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a recombinant human insulin analog that lowers blood glucose by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake, and inhibiting hepatic glucose production.
Insulin lowers blood glucose by binding to insulin receptors on target cells, activating tyrosine kinase activity, promoting glucose uptake via GLUT4 translocation, stimulating glycogen synthesis, and inhibiting gluconeogenesis and lipolysis.
Subcutaneous injection, 0.2-0.4 units/kg/day divided into two or more doses; for basal-bolus therapy, total daily dose is 0.5-1.0 units/kg/day with 50-60% as prandial insulin glulisine.
Individualized based on weight, insulin sensitivity, and metabolic needs. Type 1 diabetes: total daily dose (TDD) 0.3–1.5 units/kg/day, typically 50% basal (long-acting) and 50% prandial (rapid/short-acting). Type 2 diabetes: starting dose 0.1–0.2 units/kg/day or 10 units basal once daily, titrated based on fasting glucose. Intensive regimens use basal-bolus approach.
None Documented
None Documented
1.0-1.5 hours (terminal elimination half-life; consistent with rapid absorption and clearance; shorter than regular human insulin)
Terminal elimination half-life: 5-6 minutes for regular insulin; biphasic with initial rapid phase (4-5 min) and slower phase. Clinical context: short half-life necessitates continuous infusion or multiple daily injections.
Renal: 60-80% of dose as metabolites and parent drug; biliary/fecal: minor (20-40%)
Renal: ~60-80% (degraded in kidney); hepatic: ~20-40% (degraded in liver); only a small fraction (<1%) excreted unchanged in urine.
Category C
Category A/B
Insulin
Insulin